{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:21:19Z","timestamp":1790904079378,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173188"],"award-info":[{"award-number":["82173188"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472993"],"award-info":[{"award-number":["82472993"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014717","name":"Youth Science Fund Project","doi-asserted-by":"publisher","award":["82303566"],"award-info":[{"award-number":["82303566"]}],"id":[{"id":"10.13039\/100014717","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["22Y31900500"],"award-info":[{"award-number":["22Y31900500"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014137","name":"Shanghai Shenkang Hospital Development Center","doi-asserted-by":"publisher","award":["SHDC2024CRI060"],"award-info":[{"award-number":["SHDC2024CRI060"]}],"id":[{"id":"10.13039\/501100014137","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018625","name":"Science and Technology Innovation Plan Of Shanghai Science and Technology Commission","doi-asserted-by":"publisher","award":["21Y11906900"],"award-info":[{"award-number":["21Y11906900"]}],"id":[{"id":"10.13039\/501100018625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioactive Materials"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.bioactmat.2026.08.020","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T04:32:55Z","timestamp":1787373175000},"page":"703-718","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Harnessing necroptosis via RIPK1 degradation to potentiate radio-immunotherapy in cervical cancer"],"prefix":"10.1016","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3209-5466","authenticated-orcid":false,"given":"Tong","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4086-5928","authenticated-orcid":false,"given":"Han","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangping","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuandong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuru","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulian","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6679-5414","authenticated-orcid":false,"given":"Dalong","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjun","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keqin","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioactmat.2026.08.020_bib1","doi-asserted-by":"crossref","first-page":"E197","DOI":"10.1016\/S2214-109X(22)00501-0","article-title":"Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO global cervical cancer elimination initiative","volume":"11","author":"Singh","year":"2023","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.bioactmat.2026.08.020_bib2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"Ca-Cancer J. Clin."},{"key":"10.1016\/j.bioactmat.2026.08.020_bib3","series-title":"With or Without Bevacizumab, as Treatment for Patients with Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS \u22651)","year":"2021"},{"key":"10.1016\/j.bioactmat.2026.08.020_bib4","article-title":"First-line pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: final overall survival results of KEYNOTE-826","volume":"41","author":"Monk","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioactmat.2026.08.020_bib5","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(24)00317-9","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial","volume":"403","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.bioactmat.2026.08.020_bib6","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.annonc.2024.10.002","article-title":"Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study","volume":"36","author":"Lorusso","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioactmat.2026.08.020_bib7","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ygyno.2021.08.018","article-title":"Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and\/or metastatic cervical cancer","volume":"163","author":"O'Malley","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.bioactmat.2026.08.020_bib8","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"184","author":"Morad","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.bioactmat.2026.08.020_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102385","article-title":"Integration of immunotherapy into treatment of cervical cancer: recent data and ongoing trials","volume":"106","author":"Monk","year":"2022","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.bioactmat.2026.08.020_bib10","article-title":"Shining light on immunotherapy in metastatic urothelial carcinoma: trends and prospects","volume":"2","author":"Shah","year":"2025","journal-title":"Med. Mat."},{"key":"10.1016\/j.bioactmat.2026.08.020_bib11","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1073\/pnas.1200012109","article-title":"Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis","volume":"109","author":"Zhao","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.bioactmat.2026.08.020_bib12","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/nrm2970","article-title":"Molecular mechanisms of necroptosis: an ordered cellular explosion","volume":"11","author":"Vandenabeele","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bioactmat.2026.08.020_bib13","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nchembio.83","article-title":"Identification of RIP1 kinase as a specific cellular target of necrostatins","volume":"4","author":"Degterev","year":"2008","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bioactmat.2026.08.020_bib14","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","article-title":"Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018","volume":"25","author":"Galluzzi","year":"2018","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bioactmat.2026.08.020_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/biom10101431","article-title":"Necroptosis in intestinal inflammation and cancer: new concepts and therapeutic perspectives","volume":"10","author":"Negroni","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.bioactmat.2026.08.020_bib16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.cell.2011.11.031","article-title":"Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase","volume":"148","author":"Sun","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.bioactmat.2026.08.020_bib17","first-page":"159","volume":"352","author":"Miller","year":"2020"},{"key":"10.1016\/j.bioactmat.2026.08.020_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/VIW.20240029","article-title":"Exosomes of immune cell origin and their therapeutic potential for tumors","volume":"5","author":"Ai","year":"2024","journal-title":"View"},{"key":"10.1016\/j.bioactmat.2026.08.020_bib19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/febs.13120","article-title":"Programmed necrosis and necroptosis signalling","volume":"282","author":"Feoktistova","year":"2015","journal-title":"FEBS J."},{"key":"10.1016\/j.bioactmat.2026.08.020_bib20","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nature14191","article-title":"Necroptosis and its role in inflammation","volume":"517","author":"Pasparakis","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.bioactmat.2026.08.020_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abf6290","article-title":"ZBP1-MLKL necroptotic signaling potentiates radiation-induced antitumor immunity via intratumoral STING pathway activation","volume":"7","author":"Yang","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bioactmat.2026.08.020_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/s41568-025-00903-x","article-title":"Radiation as an immune modulator: mechanisms and implications for combination with immunotherapy","author":"Darragh","year":"2026","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioactmat.2026.08.020_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2024.04.025","article-title":"A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death","volume":"57","author":"Mannion","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.bioactmat.2026.08.020_bib24","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41578-019-0108-1","article-title":"Cancer nanomedicine for combination cancer immunotherapy","volume":"4","author":"Nam","year":"2019","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.bioactmat.2026.08.020_bib25","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41571-019-0308-z","article-title":"Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges","volume":"17","author":"Martin","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioactmat.2026.08.020_bib26","article-title":"Checkpoint Nano-PROTACs for activatable cancer photo-immunotherapy","volume":"35","author":"Zhang","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.bioactmat.2026.08.020_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114039","article-title":"Tailoring the physicochemical properties of nanomaterials for immunomodulation","volume":"180","author":"Deng","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bioactmat.2026.08.020_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2026.114957","article-title":"Engineering nanomedicine for STING pathway activation: advancing cancer immunotherapy","volume":"395","author":"Li","year":"2026","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.bioactmat.2026.08.020_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.106059","article-title":"Reversing adenosine-mediated immunosuppression in triple-negative breast cancer by synergistic chemo-immunotherapy via stimuli-responsive nanomedicines","volume":"123","author":"Cheng","year":"2026","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bioactmat.2026.08.020_bib30","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S1470-2045(20)30736-1","article-title":"NBTXR3","volume":"22","author":"Landman","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bioactmat.2026.08.020_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202208685","article-title":"Monte carlo simulation-guided design of a thorium-based metal-organic framework for efficient radiotherapy-radiodynamic therapy","volume":"61","author":"Xu","year":"2022","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.bioactmat.2026.08.020_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-55006-2","article-title":"Development of a RIPK1 degrader to enhance antitumor immunity","volume":"15","author":"Yu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioactmat.2026.08.020_bib33","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.immuni.2023.05.017","article-title":"Sublethal necroptosis signaling promotes inflammation and liver cancer","volume":"56","author":"Vucur","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.bioactmat.2026.08.020_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-018-0203-4","article-title":"Low-dose X-ray radiotherapy-radiodynamic therapy via nanoscale metal-organic frameworks enhances checkpoint blockade immunotherapy","volume":"2","author":"Lu","year":"2018","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.bioactmat.2026.08.020_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122035","article-title":"Interfering biosynthesis by nanoscale metal-organic frameworks for enhanced radiation therapy","volume":"295","author":"Fu","year":"2023","journal-title":"Biomaterials"},{"key":"10.1016\/j.bioactmat.2026.08.020_bib36","article-title":"Bifunctional metal-organic framework synergistically enhances radiotherapy and activates STING for potent cancer radio-immunotherapy","volume":"64","author":"Wang","year":"2025","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.bioactmat.2026.08.020_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.2002711","article-title":"Phosphatidylserine externalization, \"necroptotic bodies\" release, and phagocytosis during necroptosis","volume":"15","author":"Zargarian","year":"2017","journal-title":"PLoS Biol."},{"key":"10.1016\/j.bioactmat.2026.08.020_bib38","article-title":"Necroptosis execution is mediated by plasma membrane nanopores that are independent of calcium","volume":"112","author":"Quincoces","year":"2017","journal-title":"Biophys. J."},{"key":"10.1016\/j.bioactmat.2026.08.020_bib39","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1126\/science.1249361","article-title":"Activity of Protein Kinase RIPK3 Determines Whether Cells Die by Necroptosis or Apoptosis","volume":"343","author":"Newton","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.bioactmat.2026.08.020_bib40","first-page":"103","volume":"12","author":"Galluzzi","year":"2017"},{"key":"10.1016\/j.bioactmat.2026.08.020_bib41","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41568-024-00674-x","article-title":"Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity","volume":"24","author":"Meier","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioactmat.2026.08.020_bib42","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-025-03569-3","article-title":"Cracking the code of cancer immunotherapy resistance: emerging roles of pyroptosis and necroptosis","volume":"44","author":"Lei","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bioactmat.2026.08.020_bib43","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/imr.12550","article-title":"The interplay of IKK, NF-\u03baB and RIPK1 signaling in the regulation of cell death, tissue homeostasis and inflammation","volume":"277","author":"Kondylis","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.bioactmat.2026.08.020_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/s41420-023-01576-x","article-title":"5-Iodotubercidin sensitizes cells to RIPK1-dependent necroptosis by interfering with NF\u03baB signaling","volume":"9","author":"Chauhan","year":"2023","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.bioactmat.2026.08.020_bib45","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-025-02480-x","article-title":"Reversal of tumour immune evasion via enhanced MHC-Class-I antigen presentation by a dual-functional RNA regulated system","volume":"24","author":"Meng","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bioactmat.2026.08.020_bib46","doi-asserted-by":"crossref","DOI":"10.1038\/s41590-024-01792-2","article-title":"Human lung cancer harbors spatially organized stem-immunity hubs associated with response to immunotherapy","volume":"25","author":"Chen","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bioactmat.2026.08.020_bib47","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.immuni.2013.02.003","article-title":"Necroptosis: the release of damage-associated molecular patterns and its physiological relevance","volume":"38","author":"Kaczmarek","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.bioactmat.2026.08.020_bib48","doi-asserted-by":"crossref","DOI":"10.1002\/VIW.20240074","article-title":"Modelling the tumor microenvironment in vitro in prostate cancer: current and future perspectives","volume":"5","author":"Yuan","year":"2024","journal-title":"View"},{"key":"10.1016\/j.bioactmat.2026.08.020_bib49","article-title":"Engineering immune microenvironments for organoid-on-a-chip systems","volume":"3","author":"Li","year":"2026","journal-title":"Med. Mat."},{"key":"10.1016\/j.bioactmat.2026.08.020_bib50","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1007\/s40843-016-5163-4","article-title":"Cell membrane-coated nanoparticles for tumor-targeted drug delivery","volume":"60","author":"Chai","year":"2017","journal-title":"Sci. China Mater."},{"key":"10.1016\/j.bioactmat.2026.08.020_bib51","doi-asserted-by":"crossref","first-page":"22530","DOI":"10.1021\/jacs.4c06267","article-title":"Bimetallic nanoplatforms for prostate cancer treatment by interfering cellular communication","volume":"146","author":"Zhang","year":"2024","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bioactmat.2026.08.020_bib52","first-page":"112","article-title":"Recovering skin-nerve interaction by nanoscale metal-organic framework for diabetic ulcers healing","volume":"42","author":"Ji","year":"2024","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.bioactmat.2026.08.020_bib53","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-04703-w","article-title":"Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy","volume":"9","author":"Ni","year":"2018","journal-title":"Nat. Commun."}],"container-title":["Bioactive Materials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452199X26004834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452199X26004834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T08:59:01Z","timestamp":1788080341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452199X26004834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":53,"alternative-id":["S2452199X26004834"],"URL":"https:\/\/doi.org\/10.1016\/j.bioactmat.2026.08.020","relation":{},"ISSN":["2452-199X"],"issn-type":[{"value":"2452-199X","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Harnessing necroptosis via RIPK1 degradation to potentiate radio-immunotherapy in cervical cancer","name":"articletitle","label":"Article Title"},{"value":"Bioactive Materials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioactmat.2026.08.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.","name":"copyright","label":"Copyright"}]}}